Glucagon and Tirzepatide interaction
Glucagon and Tirzepatide: the Glucagon prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Glucagon (Gvoke VialDx) label · effective 2026-07-07
Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia.
Hypoglycemia in Patients with Insulinoma In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, glucagon administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia.
Intervention Monitor blood glucose when GVOKE VialDx is used as a diagnostic aid in patients receiving insulin.
Insulin: Monitor blood glucose when GVOKE VialDx is used as a diagnostic aid in patients receiving insulin.
Insulin Clincial Impact: Insulin acts antagonistically to glucagon.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.